BridgeBio Pharma Total Current Liabilities

BridgeBio Pharma (BBIO) currently reports a total current liabilities of $890M as of June 2026. That compares with $180M in the prior-year period — up 406.5% year over year. Use the charts on this page to explore BridgeBio Pharma's total current liabilities history and peer comparisons.

BridgeBio Pharma's total current liabilities increased from $180M to $890M — a 406.5% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

BridgeBio Pharma reported $890M in total current liabilities as of June 2026. That compares with $180M in the prior-year period — up 406.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $890M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for BridgeBio Pharma, and consider following BBIO for alerts when major investors trade the stock.

BridgeBio Pharma is classified in the Healthcare sector. On total current liabilities, it currently shows $890M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BBIO with unrelated industries.